PT-141 (Bremelanotide)

PDE5 inhibitors (Viagra, Cialis) work by improving penile blood flow — a purely vascular mechanism. PT-141 works in the brain, activating the neural circuits responsible for sexual desire and motivation. PT-141 addresses libido and arousal; PDE5 inhibitors address erectile mechanics. For many men and virtually all women with sexual dysfunction, the CNS layer is the limiting factor that PDE5 inhibitors cannot touch.

Yes — because the mechanism is entirely different. Several studies have shown that PT-141 produces erection and arousal in men with organic ED who are non-responders to PDE5 inhibitors. The two can also be combined: PT-141 provides the central desire signal while a PDE5 inhibitor supports the vascular response.

Nausea is the most common side effect, occurring in approximately 40% of users at the 1.75 mg dose. It is dose-dependent — lower doses (0.75-1 mg) have significantly less nausea while retaining meaningful efficacy. Facial flushing and transient blood pressure changes are also reported. Administering in the evening after eating and starting at the lower dose range minimises these effects.

No significant interaction with hormonal contraception has been identified. The melanocortinergic mechanism of PT-141 is independent of exogenous oestrogen or progesterone levels. Women on the pill who experience reduced libido (a known side effect of oral contraceptives) may find PT-141 particularly beneficial for addressing this specific deficit.

The combination is used clinically but caution is warranted with blood pressure — both can independently cause mild hypotension. Starting at conservative doses of each and monitoring blood pressure response before combining at higher doses is recommended.

Effects typically begin 45-90 minutes after injection and the arousal and desire effects last 6-12 hours. The half-life of bremelanotide is approximately 2.7 hours but receptor-level effects persist longer due to the downstream cascade initiated by MC-4R activation.